The UK’s life sciences’ crossroads: competing in a market defined by speed, scale and investment
The UK’s challenge is less about capability and more about how well it aligns with the way global pharma now operates
Read More
Jul 8, 2026 | Intelligence
The UK’s challenge is less about capability and more about how well it aligns with the way global pharma now operates
Read MoreJul 7, 2026 | Intelligence
Making launch more effective, precise, cost-effective and agile demands new thinking and new technologies
Read MoreJul 6, 2026 | Intelligence
Translating emerging science into care that works meaningfully in practice
Read MoreJun 30, 2026 | Intelligence
Industry needs to press the accelerator to adopt AI across functions to
supercharge launch excellence
Jun 16, 2026 | Intelligence
Aligning policy and public funding strategies to support brain health across Europe
Read MoreJun 12, 2026 | Intelligence
The WHO classified obesity as a chronic disease over twenty years ago – but UK policy has yet to follow
Read MoreJun 10, 2026 | Intelligence
As GLP-1s redefine the treatment landscape for obesity, they are also promising candidates to influence a wide range of disease pathways
Read MoreJun 8, 2026 | Intelligence
Regulatory changes and tariffs have created a positive climate for investment, innovation and, critically, patient access to therapies
Read MoreJun 5, 2026 | Intelligence
Until the gap between what healthcare systems can offer and how men actually engage with them is closed, outcomes will continue to deteriorate
Read MoreMar 30, 2026 | Intelligence
As new comms excellence opportunities abound, staying connected through core messaging remains critical
Read MoreMar 5, 2026 | Intelligence
Despite the GenAI fervour, there is an acute need to prepare organisations to understand which specific tools they need and how to use them
Read MoreFeb 25, 2026 | Intelligence
AI has graduated from being a procurer of efficiencies to seemingly an enabler of unimagined possibilities
Read More
